Novo diabetes site adds new tools to self-manage

Share this article:
Novo Nordisk has unveiled a revamped diabetes care Web site to communicate with patients seeking help in the self-management of the disease.

ChangingDiabetes-us.com features new tools and content developed in response to findings from the Diabetes Attitudes, Wishes and Needs (DAWN) study, a 5,426-patient survey commissioned by Novo Nordisk.

“The DAWN Study has given us valuable insights into how people cope with diabetes at diagnosis and throughout the disease process,” said Susan Harrow Rago, associate director, patient services & professional relations, in a statement.

According to Rago, the site’s new tools will help diabetes patients collaborate more effectively to develop treatment programs tailored to their individual needs.

Content highlights include:
• Guide Me—a feature allowing diabetes patients to customize the site content based on their personal diagnosis.
• Diabetes Care Plan—an interactive tool that helps users track, manage and set goals for their diabetes care.
• My Priorities—a feature to help patients develop personal diabetes care goals and a psychosocial profile.

Users can also sign up to receive regular e-mail communications on diabetes topics from Novo Nordisk and link to divabetic.org, a diabetes outreach site for women.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...